COMPANY

OVERVIEW

With creative innovation and visionary leadership, we strive to become a world-class company.

MediArk develops breakthrough products in chemistry and biotechnology based on its proprietary advanced porous-material technologies. By precisely controlling nano- and micro-scale particle sizes, tailoring pore structures, modifying surfaces, and enabling high-efficiency drug loading, we create next-generation solutions across multiple sectors—including adsorbents, catalysts, vaccines, targeted therapeutics, synthetic pharmaceuticals, and cosmeceutical formulations. We are committed to translating our cutting-edge materials science into commercialized products that deliver meaningful impact to industries and consumers worldwide.

CEO Se-Na Kim

이미지명

CEO

Se-Na Kim

  • PhD in bioengineering from Seoul National University

  • Senior researcher, Seoul National University Medical Research Institute

  • Rich experience in developing treatments for incurable diseases

Major field

Biomaterials/drug delivery

Biography

  • Graduated from Seoul National University with a doctoral degree in bioengineering.

  • Postdoctoral researcher, Seoul National University Medical Research Institute (2019-2020)

  • Full-time researcher, Medytox Biopharmaceutical Development Department (2020-2021)

  • Senior Researcher, Seoul National University Medical Research Institute (2021-2022)

  • CEO of Mediark Inc. (2022-present)

  • Adjunct Assistant Professor, Chungbuk National University (2023-present)

이미지명

CTO

Wooram Park

  • PhD in Biotechnology from Catholic University

  • Postdoctoral researcher at Northwestern University

  • Rich experience in gene therapy development

Major field

Nanoparticles/gene delivery

Biography

  • Graduated from the Catholic University of Korea, Department of Biotechnology, Ph.D.

  • Northwestern University Postdoctoral Research Fellow (2015-2017)

  • Assistant Professor, Department of Biomedical and Chemical Engineering, Catholic University (2020~2022)

  • Assistant Professor, Department of Convergence Biotechnology, Sungkyunkwan University (2022-present)

  • CTO of Mediark Inc. (2022-presen

이미지명

CSO

Chun Gwon Park

  • PhD in bioengineering from Seoul National University

  • Harvard University Postdoctoral Researcher

  • Rich experience developing immunotherapy treatments

Major field

Immunotherapy/drug delivery

Biography

  • Graduated from Seoul National University with a doctoral degree in bioengineering.

  • Senior researcher, Seoul National University Medical Research Institute (2014-2015)

  • Dana-Farber Cancer Institute/Harvard Medical School Research Fellow (2015-2018)

  • Associate Professor, Department of Global Biomedical Engineering, Sungkyunkwan University (2019-present)

  • CSO of Mediark Inc. (2022-present)

Management philosophy

Contribution to human society through development of next-generation innovative technologies

A respected company through people-centered ethical management

Challenging technology management that creates new value